Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Refluzero
- Development stage
- Unknown
- Lead developer
- Malesci Istituto Farmacobiologico
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
Refluzero is a combination product developed by Malesci Pharmacobiological Institute, a subsidiary of the Menarini Group, indicated for the symptomatic treatment of gastroesophageal reflux disease (GERD). The formulation consists of chondroitin sulfate, hyaluronic acid, and aluminum hydroxide. It operates through a dual mechanism of action: aluminum hydroxide acts as an antacid to neutralize gastric acidity, while chondroitin sulfate and hyaluronic acid provide a mechanical barrier by adhering to the esophageal mucosa. This protective film shields the esophageal lining from the corrosive effects of gastric acid and pepsin, thereby alleviating symptoms such as heartburn, acid regurgitation, and epigastric pain. Refluzero is typically classified as a medical device in European markets and is available in oral dosage forms including chewable tablets and oral suspension sticks.
- Brand names
- Refluzero
Beyond the preview
Go deeper on Refluzero.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Refluzero.